Sorry, you need to enable JavaScript to visit this website.

A Study of Talazoparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA Repair Defects

A Study of Talazoparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA Repair Defects. TALAPRO-1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone.

Category & Conditions: Cancer
Medicine: TALZENNA™(TALAZOPARIB) CAPSULES
ClinicalTrials.gov Identifier (NCT): NCT03148795
Protocol ID: C3441006 (MDV3800-06)
    Share
PrintDownload
Open Plain Language Summary Result: Click here